TY - JOUR
T1 - Mechanisms and functions of chemerin in cancer
T2 - Potential roles in therapeutic intervention
AU - Shin, Woo Jae
AU - Zabel, Brian A.
AU - Pachynski, Russell K.
N1 - Funding Information:
The authors thank Christina Mizerny and Kayla Corman for administrative support. RP is funded by American Cancer Society #125078-MRSG-13-244-01-LIB and a Kimmel Scholar Award. BZ was supported by 3R01AI079320, R01CA169354 (E.C. Butcher, PI), and the Emerson Collective Cancer Research Fund.
Publisher Copyright:
© 2007 - 2018 Frontiers Media S.A.
PY - 2018/11/30
Y1 - 2018/11/30
N2 - Chemerin [RARRES2 [retinoic acid receptor responder 2], TIG2 [tazarotene induced gene 2 (TIG2)]] is a multifunctional cytokine initially described in skin cultures upon exposure to the synthetic retinoid tazarotene. Its secreted pro-form, prochemerin, is widely expressed, found systemically, and is readily converted into active chemerin by various proteases. Subsequent studies elucidated major roles of chemerin as both a leukocyte chemoattractant as well as an adipokine. Chemerin's main chemotactic receptor, the G-protein coupled receptor CMKLR1, is expressed on macrophages, dendritic, and NK cells. With respect to its role in immunology, chemerin mediates trafficking of these cells to sites of inflammation along its concentration gradient, and likely helps coordinate early responses, as it has been shown to have antimicrobial and angiogenic properties, as well. Recently, there has been mounting evidence that chemerin is an important factor in various cancers. As with its role in immune responses-where it can act as both a pro- and anti-inflammatory mediator - The potential functions or correlations chemerin has in or with cancer appears to be context dependent. Most studies, however, suggest a downregulation or loss of chemerin/RARRES2 in malignancies compared to the normal tissue counterparts. Here, we perform a comprehensive review of the literature to date and summarize relevant findings in order to better define the roles of chemerin in the setting of the tumor microenvironment and tumor immune responses, with an ultimate focus on the potential for therapeutic intervention.
AB - Chemerin [RARRES2 [retinoic acid receptor responder 2], TIG2 [tazarotene induced gene 2 (TIG2)]] is a multifunctional cytokine initially described in skin cultures upon exposure to the synthetic retinoid tazarotene. Its secreted pro-form, prochemerin, is widely expressed, found systemically, and is readily converted into active chemerin by various proteases. Subsequent studies elucidated major roles of chemerin as both a leukocyte chemoattractant as well as an adipokine. Chemerin's main chemotactic receptor, the G-protein coupled receptor CMKLR1, is expressed on macrophages, dendritic, and NK cells. With respect to its role in immunology, chemerin mediates trafficking of these cells to sites of inflammation along its concentration gradient, and likely helps coordinate early responses, as it has been shown to have antimicrobial and angiogenic properties, as well. Recently, there has been mounting evidence that chemerin is an important factor in various cancers. As with its role in immune responses-where it can act as both a pro- and anti-inflammatory mediator - The potential functions or correlations chemerin has in or with cancer appears to be context dependent. Most studies, however, suggest a downregulation or loss of chemerin/RARRES2 in malignancies compared to the normal tissue counterparts. Here, we perform a comprehensive review of the literature to date and summarize relevant findings in order to better define the roles of chemerin in the setting of the tumor microenvironment and tumor immune responses, with an ultimate focus on the potential for therapeutic intervention.
KW - CCRL2
KW - CMKLR1
KW - GPR1
KW - RARRES2
KW - cancer
KW - chemerin
KW - chemoattractant
KW - cytokine
UR - http://www.scopus.com/inward/record.url?scp=85057629943&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2018.02772
DO - 10.3389/fimmu.2018.02772
M3 - Review article
C2 - 30555465
AN - SCOPUS:85057629943
SN - 1664-3224
VL - 9
JO - Frontiers in immunology
JF - Frontiers in immunology
IS - NOV
M1 - 2772
ER -